Alkhaffaf Bilal, Blazeby Jane M, Williamson Paula R, Bruce Iain A, Glenny Anne-Marie
Department of Oesophago-Gastric Surgery, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
Department of Oesophago-Gastric Surgery, Salford Royal Hospital, Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
BMJ Open. 2018 Oct 17;8(10):e021796. doi: 10.1136/bmjopen-2018-021796.
The development of clinical guidelines for the surgical management of gastric cancer should be based on robust evidence from well-designed trials. Being able to reliably compare and combine the outcomes of these trials is a key factor in this process.
To examine variation in outcome reporting by surgical trials for gastric cancer and to identify outcomes for prioritisation in an international consensus study to develop a core outcome set in this field.
Systematic literature searches (Evidence Based Medicine, MEDLINE, EMBASE, CINAHL, ClinicalTrials.gov and WHO ICTRP) and a review of study protocols of randomised controlled trials, published between 1996 and 2016.
Therapeutic surgical interventions for gastric cancer. Outcomes were listed verbatim, categorised into groups (outcome themes) and examined for definitions and measurement instruments.
Of 1919 abstracts screened, 32 trials (9073 participants) were identified. A total of 749 outcomes were reported of which 96 (13%) were accompanied by an attempted definition. No single outcome was reported by all trials. 'Adverse events' was the most frequently reported 'outcome theme' in which 240 unique terms were described. 12 trials (38%) classified complications according to severity, with 5 (16%) using a formal classification system (Clavien-Dindo or Accordion scale). Of 27 trials which described 'short-term' mortality, 15 (47%) used one of five different definitions. 6 out of the 32 trials (19%) described 'patient-reported outcomes'.
Reporting of outcomes in gastric cancer surgery trials is inconsistent. A consensus approach to develop a minimum set of well-defined, standardised outcomes to be used by all future trials examining therapeutic surgical interventions for gastric cancer is needed. This should consider the views of all key stakeholders, including patients.
胃癌手术管理临床指南的制定应以精心设计的试验所提供的有力证据为基础。能够可靠地比较和整合这些试验的结果是这一过程中的关键因素。
研究胃癌手术试验结果报告的差异,并确定在一项国际共识研究中需要优先考虑的结果,以制定该领域的核心结局集。
系统文献检索(循证医学、医学期刊数据库、荷兰医学文摘数据库、护理学与健康领域数据库、美国国立医学图书馆临床试验注册库和世界卫生组织国际临床试验平台)以及对1996年至2016年间发表的随机对照试验研究方案的回顾。
胃癌的治疗性手术干预。结果逐字列出,分为几组(结局主题),并检查其定义和测量工具。
在筛选的1919篇摘要中,确定了32项试验(9073名参与者)。共报告了749项结果,其中96项(13%)伴有尝试性定义。没有一项结果在所有试验中都有报告。“不良事件”是报告最频繁的“结局主题”,其中描述了240个独特术语。12项试验(38%)根据严重程度对并发症进行分类,5项试验(16%)使用正式分类系统(Clavien-Dindo或手风琴量表)。在描述“短期”死亡率的27项试验中,15项(47%)使用了五种不同定义中的一种。32项试验中有6项(19%)描述了“患者报告的结果”。
胃癌手术试验的结果报告不一致。需要一种共识方法来制定一套最少的、定义明确、标准化的结果,供未来所有研究胃癌治疗性手术干预的试验使用。这应该考虑所有关键利益相关者的意见,包括患者。